drugset
drugset / Trial / NCT05788965

Semaglutide in CFRD

NCT05788965 ↗

Phase 2/3 Completed 8 enrolled University of Minnesota Cystic Fibrosis Foundation · collab
NaSingle-groupOpen-labelTreatment

Summary

This open label, single arm pilot study, will examine the safety and tolerability of GLP-1RA semaglutide as an add-on therapy to insulin for overweight/obese adult patients with cystic fibrosis related diabetes (CFRD).

Timeline

Start
2023-10-16
Primary completion
2024-12-23
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 1 mg Subcutaneous

Indications

cystic fibrosis cystic fibrosis-related diabetes